A novel LC–MS/MS assay to quantify dermatan sulfate in cerebrospinal fluid as a biomarker for mucopolysaccharidosis II. (4th June 2018)

• Record Type: Journal Article
• Authors: Pan, Peng; Chen, Mu; Zhang, Zhiling; Corte, Amauri Dalla; Souza, Carolina; Giugliani, Roberto; Pan, Luying; Qiu, Yongchang; Amaravadi, Lakshmi; Wu, Jiang
• Is Part Of: Bioanalysis. Volume 10:Number 11(2018)
• Page Start: 825
• Page End: 838
• Publication Date: 2018-06-04
• Subjects: cerebrospinal fluid -- dermatan sulfate -- fit-for-purpose validation -- glycosaminoglycans -- ion pairing LC–MS/MS -- mucopolysaccharidosis II -- surrogate matrix; Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio-2018-0025
• Languages: English
• ISSNs: 1757-6180

Abstract

Aim: The study aimed to develop an LC–MS/MS assay to measure dermatan sulfate (DS) in human cerebrospinal fluid (CSF).Methods & results: DS was quantified by ion pairing LC–MS/MS analysis of the major disaccharides derived from chondroitinase B digestion. Artificial CSF was utilized as a surrogate for calibration curve preparation. The assay was fully validated, with a linear range of 20.0–4000 ng/ml, accuracy within ±20%, and precision of ≤20%. CSF samples from mucopolysaccharidoses (MPS) II patients showed an average of 11-fold increase in DS levels compared with controls.Conclusion: The described assay is capable of differentiating DS levels in the CSF of MPS II patients from controls and can be used to monitor disease progression and therapeutic responses.